This is a preview of subscription content, log in via an institution to check access.
Notes
can include wheezing or difficulty breathing; swelling of the face or throat; hives or flushing; itching; abdominal cramping or pain, or vomiting; chest or back pain; and hypotension or shock.
Reference
US Food and Drug Administration. Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter - Anaphylaxis and Other Serious Hypersensitivity Reactions. Internet Document : 16 Jan 2018. Available from: URL: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm592592.htm
Rights and permissions
About this article
Cite this article
Rolapitant linked with anaphylaxis and hypersensitivity. Reactions Weekly 1686, 7 (2018). https://doi.org/10.1007/s40278-018-41071-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-41071-6